Residency · Residency · Chronic Pain Management
NSAIDs and COX-2 Inhibitors in Chronic Pain
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) remain among the most widely prescribed analgesics worldwide. Their mechanism centers on inhibition of cyclooxygenase (COX) enzymes, which catalyze the conversion of arachidonic acid to prostaglandins and thromboxanes. Understanding the distinction between COX-1 (constitutively expressed and protective of gastric mucosa and platelet function) and COX-2 (inducible and upregulated at sites of inflammation) is fundamental to rational prescribing in chronic pain.
Mechanisms of Action
Non-selective NSAIDs such as ibuprofen, naproxen, diclofenac, and ketorolac inhibit both COX-1 and COX-2. COX-2 selective inhibitors such as celecoxib and etoricoxib preferentially block COX-2, reducing prostaglandin E2 (PGE2) synthesis at inflammatory sites while relatively sparing COX-1-mediated gastroprotection.
NSAIDs work through both peripheral and central mechanisms. Peripherally, reduction of PGE2 decreases peripheral nociceptor sensitization -- the same inflammatory soup mechanism discussed in the context of peripheral sensitization. Centrally, COX-2 is constitutively expressed in the spinal dorsal horn, and its inhibition reduces central sensitization and wind-up phenomena. Additional anti-inflammatory effects include reduction of bradykinin sensitization and decreased neutrophil aggregation.
<image>Detailed pharmacological diagram showing the arachidonic acid cascade, with phospholipase A2 releasing arachidonic acid from cell membranes, bifurcating into COX-1 and COX-2 pathways, illustrating where non-selective NSAIDs and COX-2 selective inhibitors act, with downstream prostaglandin and thromboxane products labeled including PGE2, PGI2, and TXA2</image>
Comparative Efficacy in Chronic Pain Conditions
Osteoarthritis
NSAIDs demonstrate moderate effect sizes (standardized mean difference of approximately 0.29) for osteoarthritis pain. In network meta-analyses, diclofenac 150 mg/day shows the highest efficacy among oral NSAIDs, while celecoxib 200 mg/day demonstrates comparable efficacy to non-selective NSAIDs. Topical NSAIDs, particularly diclofenac gel, provide localized relief with reduced systemic exposure.
Inflammatory Arthritis
NSAIDs are more effective in conditions with a prominent inflammatory component. Naproxen 1000 mg/day remains a first-line option for ankylosing spondylitis. COX-2 inhibitors offer comparable anti-inflammatory efficacy with improved gastrointestinal tolerability.
Chronic Low Back Pain
Evidence supports short-to-medium term benefit from NSAIDs for chronic low back pain, though long-term efficacy data are limited. The number needed to treat (NNT) is approximately 6 for clinically meaningful pain reduction. NSAIDs are more effective than acetaminophen for this indication.
Cardiovascular Risk Profile
All NSAIDs carry some degree of cardiovascular risk, with the notable exception of naproxen at standard doses. The withdrawal of rofecoxib (Vioxx) in 2004 highlighted the prothrombotic risk inherent in selective COX-2 inhibition. The PRECISION trial subsequently demonstrated that celecoxib at doses up to 200 mg twice daily was non-inferior to naproxen and ibuprofen for cardiovascular outcomes. Among commonly used non-selective NSAIDs, diclofenac carries the highest cardiovascular risk. Risk is dose-dependent and increases with duration of use.
The mechanism is straightforward: COX-2 inhibition reduces endothelial prostacyclin (PGI2) production without affecting COX-1-mediated thromboxane A2 synthesis in platelets, creating a prothrombotic imbalance that favors platelet aggregation and vasoconstriction.
<image>Comparative risk diagram showing cardiovascular and gastrointestinal risk profiles of common NSAIDs arranged on a two-axis grid, with naproxen, ibuprofen, diclofenac, and celecoxib plotted according to their relative CV risk on the x-axis and GI risk on the y-axis, with color coding from green (lower risk) to red (higher risk)</image>
Gastrointestinal Risk
Non-selective NSAIDs increase the risk of gastrointestinal bleeding 3-5 fold. Risk factors for NSAID gastropathy include age over 65, history of peptic ulcer, concurrent anticoagulant or corticosteroid use, and H. pylori infection. COX-2 selective inhibitors reduce the risk of upper GI events by approximately 50%.
Several gastroprotective strategies are available for chronic NSAID use. Co-prescription of proton pump inhibitors (PPIs) with non-selective NSAIDs is the most common approach. COX-2 selective inhibitors should be used in patients at high GI risk. For patients with prior GI bleeding (the highest risk group), a COX-2 inhibitor plus a PPI provides the best protection. Misoprostol co-therapy is an alternative but is limited by its own GI side effects and poor compliance.
Renal Effects
Both COX-1 and COX-2 are expressed in the kidney, where prostaglandins maintain renal blood flow and glomerular filtration. NSAIDs can cause acute kidney injury, sodium and water retention, hyperkalemia, and hypertension. Risk is elevated in patients with pre-existing renal insufficiency, heart failure, or volume depletion, and in those concurrently taking ACE inhibitors or ARBs -- the so-called "triple whammy" combination that dramatically increases the risk of acute kidney injury. COX-2 inhibitors carry equivalent renal risk to non-selective NSAIDs. Chronic NSAID use is associated with analgesic nephropathy and chronic interstitial nephritis.
Evidence-Based Prescribing Guidelines for Chronic Use
| NSAID | COX Selectivity | Relative CV Risk | Relative GI Risk | Key Notes |
|---|---|---|---|---|
| Naproxen | Non-selective | Lowest | Moderate-High | Preferred in elevated CV risk |
| Ibuprofen | Non-selective | Moderate | Moderate | Interferes with aspirin antiplatelet effect |
| Diclofenac | Non-selective (COX-2 preferential) | Highest among non-selective | Moderate-High | Highest analgesic efficacy |
| Celecoxib | COX-2 selective | Moderate (non-inferior to naproxen per PRECISION) | Lowest | Preferred in elevated GI risk |
| Ketorolac | Non-selective | Moderate | High | Short-term use only (≤5 days) |
The guiding principle is to use the lowest effective dose for the shortest necessary duration. Before initiating NSAID therapy, cardiovascular, GI, and renal risk should be assessed. Naproxen is preferred in patients with elevated cardiovascular risk. Celecoxib is preferred in patients with elevated GI risk who do not have elevated cardiovascular risk. Blood pressure, renal function (BUN and creatinine), and CBC should be monitored periodically. Concurrent use of multiple NSAIDs, including interactions with low-dose aspirin, should be avoided. Topical NSAIDs should be considered for localized conditions to minimize systemic exposure. The benefit-risk ratio should be reassessed at regular intervals, at minimum every 3-6 months.
<image>Clinical decision algorithm flowchart for NSAID selection in chronic pain, starting with assessment of cardiovascular risk and gastrointestinal risk, branching to recommend naproxen plus PPI for high CV risk patients, celecoxib for high GI risk patients, and celecoxib plus PPI for patients with both high GI and high CV risk, with renal function checkpoints at each decision node</image>
Clinical Pearls
Diclofenac has the highest analgesic efficacy among oral NSAIDs but carries the greatest cardiovascular risk among non-selective agents -- this tension between efficacy and safety must be explicitly considered for each patient. The PRECISION trial established that celecoxib at moderate doses is non-inferior to ibuprofen and naproxen for cardiovascular safety, which should inform prescribing decisions. Always check for the "triple whammy" combination of NSAID plus ACE inhibitor or ARB plus diuretic, which dramatically increases the risk of acute kidney injury. Topical diclofenac achieves therapeutic synovial fluid concentrations with plasma levels approximately 5-10% of oral dosing, making it an attractive option for localized joint pain. NSAIDs can attenuate the cardioprotective effect of low-dose aspirin when taken concurrently; patients should be advised to take aspirin 30 minutes before ibuprofen to preserve aspirin's antiplatelet effect.
References
- da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21-e33.
- Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519-2529.
- Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613-624.
- Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis. Eur J Intern Med. 2015;26(4):285-291.
